Literature DB >> 24726840

Reduced phosphorylation of Stat3 at Ser-727 mediated by casein kinase 2 - protein phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells.

Tapashi Mandal1, Arijit Bhowmik2, Anirban Chatterjee3, Uttara Chatterjee4, Sandip Chatterjee5, Mrinal Kanti Ghosh6.   

Abstract

Signal transducer and activator of transcription 3 (Stat3) is a transcription factor that is involved in cell survival and proliferation and has been found to be persistently activated in most human cancers mainly through its phosphorylation at Tyr-705. However, the role and regulation of Stat3 Ser-727 phosphorylation in cancer cells have not been clearly evaluated. In our findings, correlation studies on the expression of CK2 and Stat3 Ser-727 phosphorylation levels in human glioma patient samples as well as rat orthotopic tumor model show a degree of negative correlation. Moreover, brain tumor cell lines were treated with various pharmacological inhibitors to inactivate the CK2 pathway. Here, increased Stat3 Ser-727 phosphorylation upon CK2 inhibition was observed. Overexpression of CK2 (α, α' or β subunits) by transient transfection resulted in decreased Stat3 Ser-727 phosphorylation. Stat3 Tyr-705 residue was conversely phosphorylated in similar situations. Interestingly, we found PP2A, a protein phosphatase, to be a mediator in the negative regulation of Stat3 Ser-727 phosphorylation by CK2. In vitro assays prove that Ser-727 phosphorylation of Stat3 affects the transcriptional activity of its downstream targets like SOCS3, bcl-xl and Cyclin D1. Stable cell lines constitutively expressing Stat3 S727A mutant showed increased survival, proliferation and invasion which are characteristics of a cancer cell. Rat tumor models generated with the Stat3 S727A mutant cell line formed more aggressive tumors when compared to the Stat3 WT expressing stable cell line. Thus, in glioma, reduced Stat3 Ser-727 phosphorylation enhances tumorigenicity which may be regulated in part by CK2-PP2A pathway.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  CK2; Glioma; PP2A; pStat3(S727); pStat3(Y705)

Mesh:

Substances:

Year:  2014        PMID: 24726840     DOI: 10.1016/j.cellsig.2014.04.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  31 in total

1.  Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

Authors:  Fatima Qaiser; Janeen H Trembley; Sarah Sadiq; Iqbal Muhammad; Rubina Younis; Shoaib Naiyar Hashmi; Badar Murtaza; Thomas S Rector; Abdul Khaliq Naveed; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

2.  The DEAD box protein p68: a crucial regulator of AKT/FOXO3a signaling axis in oncogenesis.

Authors:  M Sarkar; V Khare; K K N Guturi; N Das; M K Ghosh
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

Review 3.  New insights into targeting mitochondria in ischemic injury.

Authors:  Jingjing Jia; Haiqiang Jin; Ding Nan; Weiwei Yu; Yining Huang
Journal:  Apoptosis       Date:  2021-03-09       Impact factor: 4.677

4.  Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma.

Authors:  Simona Ruggieri; Roberto Tamma; Nicoletta Resta; Francesco Albano; Nicoletta Coccaro; Daria Loconte; Tiziana Annese; Mariella Errede; Giorgina Specchia; Rebecca Senetta; Paola Cassoni; Domenico Ribatti; Beatrice Nico
Journal:  Oncotarget       Date:  2017-05-09

Review 5.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

6.  The DEAD box protein p68: a novel coactivator of Stat3 in mediating oncogenesis.

Authors:  M Sarkar; V Khare; M K Ghosh
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

7.  Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.

Authors:  Brent J Tierney; Georgia A McCann; Shan Naidu; Kellie S Rath; Uksha Saini; Ross Wanner; Periannan Kuppusamy; Adrian Suarez; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2014-07-16       Impact factor: 5.482

Review 8.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

9.  2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.

Authors:  Benoît Bestgen; Irina Kufareva; Weiguang Seetoh; Chris Abell; Rolf W Hartmann; Ruben Abagyan; Marc Le Borgne; Odile Filhol; Claude Cochet; Thierry Lomberget; Matthias Engel
Journal:  J Med Chem       Date:  2019-02-13       Impact factor: 7.446

10.  Bioassay-guided isolation of cantharidin from blister beetles and its anticancer activity through inhibition of epidermal growth factor receptor-mediated STAT3 and Akt pathways.

Authors:  Jaemoo Chun; Min Kyoung Park; Hyejin Ko; Kyungjin Lee; Yeong Shik Kim
Journal:  J Nat Med       Date:  2018-07-24       Impact factor: 2.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.